Companies just looking to get their start in the biotech and life sciences field often have limited funds and lots of time ahead of them before they get to FDA approval. And as the biotech industry faces what could be a long bear market due to inflation and rising interest rates, the costs of business from research to manufacturing have increased significantly. Now more than ever funding can be hard to come by, especially for those just getting started.